Xbrane Biopharma AB

At a glance

Most recent filing on January 20, 2025 — a sale by Karl Martin Erik Åmark on Jan 17, 2025.

We hold 156 visible filings, going back to October 24, 2016.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

5 of 156 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 156. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Karl Martin Erik Åmark Chief executive officer
315,054 SEKOpen-market sale
TradedJan 17, 2025FiledJan 20, 2025
Karl Martin Erik Åmark Chief executive officer
318,782 SEKOpen-market buy
TradedJan 17, 2025FiledJan 20, 2025
Karl Martin Erik Åmark Chief executive officer
256,500 SEKOpen-market buy
TradedJan 16, 2025FiledJan 20, 2025
Karl Martin Erik Åmark Chief executive officer
256,500 SEKOpen-market sale
TradedJan 16, 2025FiledJan 20, 2025
Siavash Bashiri Deputy chief executive officer
256,500 SEKOpen-market buy
TradedJan 16, 2025FiledJan 19, 2025